Micari 2005.

Methods	Date of publication: 2005 Design: not reported Allocation: randomised Country: USA
Participants	Diagnosis: acute STEMI for PPCI Number: 30 (adenosine 14; control 16) Age, years: adenosine (mean 57), control (mean 57) Sex: 67% men Inclusion: symptoms consistent with myocardial ischaemia for 30 minutes and 2‐mm ST‐segment elevation in 2 contiguous electrocardiographic leads; STEMI presenting within 6 hours from the onset of AMI Exclusion: history of AMI; wall motion abnormalities in 1 vascular territory; cardiomyopathy Withdrawals or losses to follow‐up: not reported
Interventions	Adenosine Dose: 50 to 70 μg/kg/min for 3 hours Route of administration: intravenous Timing: initiated < 15 minutes before the procedure Control Dose: normal saline for 3 hours Route of administration: intravenous Timing: initiated < 15 minutes before the procedure
Outcomes	Death Non‐fatal MI (no recurrent ischaemic events) TIMI (RR 1.14, 95% Cl 0.18 to 7.08) Side effects: AV block Follow‐up: 4 weeks
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Patients with ST‐elevation AMI referred for percutaneous coronary stenting were randomized to receive intravenous adenosine"; no further description
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) All outcomes	Low risk	"The thrombolysis In myocardial infarction flow grade after PCI was assessed by a reader blinded to the clinical and echocardiographic data" "Analysis of the myocardial contrast echocardiographic data was performed blinded to the clinical and angiographic data" "The analysis of wall motion index was performed blinded to all other data"
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data were reported
Selective reporting (reporting bias)	Low risk	All outcomes stated in Methods are reported in Results
Other bias	Low risk	Not obvious